Evidence map›Paper›PMID 40229380›Full record

ReviewNature biotechnology2025

Engineering innate immune cells for cancer immunotherapy.

Mubin Tarannum, Xizhong Ding, Marta Barisa, Sabrina Hu, John Anderson, Rizwan Romee, Jin Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Engineering Immune Cell to Counteract Aging and Aging-Associated Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mubin Tarannum *Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Xizhong Ding *Center for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, and Bone Marrow Transplantation Center of the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
Marta Barisa *Cancer Section, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0001-7846-6810
Sabrina HuDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
John AndersonCancer Section, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK. j.anderson@ucl.ac.uk.
Rizwan RomeeDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. rizwan_romee@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-9077-4736
Jin ZhangCenter for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, and Bone Marrow Transplantation Center of the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. zhgene@zju.edu.cn.ORCID http://orcid.org/0000-0003-0197-3624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immune cells, including natural killer cells, macrophages and γδ T cells, are gaining prominence as promising candidates for cancer immunotherapy. Unlike conventional T cells, these cells possess attributes such as inherent antitumor activity, rapid immune responses, favorable safety profiles and the ability to target diverse malignancies without requiring prior antigen sensitization. In this Review, we examine the engineering strategies used to enhance their anticancer potential. We discuss challenges associated with each cell type and summarize insights from preclinical and clinical work. We propose strategies to address existing barriers, providing a perspective on the advancement of innate immune engineering as a powerful modality in anticancer treatment.

Indexed as

Cell EngineeringImmunity, InnateImmunotherapyNeoplasmsAnimalsHumansKiller Cells, NaturalMacrophages

Identifiers

PMID40229380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.